https://biotechmorning.com/news/pharma-billion-dollar-ai-drug-discovery-bet Biotech Morning en 2026-05-31T14:23:40.679Z Pharma's $10 Billion Bet That Robots Can Find Better Drugs Than Humans https://biotechmorning.com/news/aacr-2026-lung-cancer-three-horse-race Biotech Morning en 2026-05-31T14:22:40.492Z Lung Cancer's Three-Horse Race Just Got a Lot More Interesting https://biotechmorning.com/news/biontech-bms-pfizer-bispecific-nsclc-endpoint-split Biotech Morning en 2026-05-31T14:21:45.442Z Two Pharma Giants, One Drug Class, Totally Different Bets https://biotechmorning.com/news/lilly-kelonia-in-vivo-car-t-asco-2026 Biotech Morning en 2026-05-31T14:20:49.733Z Lilly Paid $3.25 Billion for a CAR-T That Skips the Factory https://biotechmorning.com/news/biotech-confidence-soaring-workforce-different-story Biotech Morning en 2026-05-31T14:19:54.157Z Biotech's Confidence Is Soaring. Its Workforce Tells a Different Story. https://biotechmorning.com/news/biotech-funding-extensions-avoid-down-rounds Biotech Morning en 2026-05-31T14:18:56.340Z Biotech's Favorite New Trick for Pretending Everything Is Fine https://biotechmorning.com/news/fda-rare-disease-biotech-uncertainty Biotech Morning en 2026-05-31T14:18:05.207Z The FDA Keeps Changing Its Mind, and Rare Disease Biotechs Are Spiraling https://biotechmorning.com/news/first-pill-stops-covid-before-it-starts Biotech Morning en 2026-05-31T14:17:07.200Z The First Pill That Stops COVID Before It Starts https://biotechmorning.com/news/gilead-tubulis-asco-2026-ovarian-cancer-adc-data Biotech Morning en 2026-05-31T14:16:16.082Z What Gilead Saw for $3.15 Billion Before Anyone Else Did https://biotechmorning.com/news/car-t-pioneer-wondercel-gene-editing-free Biotech Morning en 2026-05-30T14:19:08.873Z The CAR-T Pioneer Who Thinks Gene Editing Is the Wrong Answer https://biotechmorning.com/news/biotech-ipo-window-hemab-seaport-556-million Biotech Morning en 2026-05-30T14:18:15.494Z Half a Billion Dollars in One Day: Biotech's IPO Window Just Blew Wide Open https://biotechmorning.com/news/bms-hengrui-15-billion-deal-preclinical Biotech Morning en 2026-05-30T14:17:21.685Z BMS Just Bet $15.2 Billion on 13 Drugs That Don't Exist Yet https://biotechmorning.com/news/astrazeneca-approval-bid-after-phase-3-miss Biotech Morning en 2026-05-30T14:16:23.633Z AstraZeneca's Boldest Bet: Filing for Approval After Failing the Test https://biotechmorning.com/news/agios-tebapivat-phase-2-mds-failure Biotech Morning en 2026-05-30T14:15:32.047Z Agios Bet Big That a Blood Cell Fix Could Fight Cancer. It Couldn't. https://biotechmorning.com/news/zaynich-antibiotic-outgunned-last-line-of-defense Biotech Morning en 2026-05-30T14:14:40.902Z The Antibiotic That Outgunned the Last Line of Defense https://biotechmorning.com/news/bms-celmods-double-pfs-myeloma-asco-2026 Biotech Morning en 2026-05-30T14:13:54.224Z BMS Just Found a Way to Make Myeloma's Best Drug Class Even Better